Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.

<h4>Background</h4>Serum des-γ-carboxy prothrombin (DCP) is a hepatocellular carcinoma (HCC) tumor marker that can be used to assess patient prognosis. Since the value of DCP in predicting the prognosis of hepatocellular carcinoma patients treated with transarterial chemotherapy remains...

Full description

Bibliographic Details
Main Authors: Ming Yang, Xuejun Zhang, Jinlong Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0225170
id doaj-7ed058c454fd489d9aa1d602fdea8657
record_format Article
spelling doaj-7ed058c454fd489d9aa1d602fdea86572021-03-04T10:23:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011411e022517010.1371/journal.pone.0225170Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.Ming YangXuejun ZhangJinlong Liu<h4>Background</h4>Serum des-γ-carboxy prothrombin (DCP) is a hepatocellular carcinoma (HCC) tumor marker that can be used to assess patient prognosis. Since the value of DCP in predicting the prognosis of hepatocellular carcinoma patients treated with transarterial chemotherapy remains controversial, we performed a meta-analysis of previous clinical studies.<h4>Methods</h4>A systematic literature search was performed using PubMed, the MEDLINE database, EMBASE, and the Cochrane Library in accordance with the PRISMA guidelines. The hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the effect size.<h4>Results</h4>Six respective cohort studies including a total of 943 cases were identified. The pooled results showed that low DCP was associated with a favorable overall survival (OS)(HR 0.653, 95% CI 0.444-0.960), and DCP response was associated with increased OS (HR 0.387,95% CI 0.215-0.697) and progression-free survival (PFS) (HR 0.42,95% CI 0.23-0.74) in HCC patients treated with transarterial chemotherapy.<h4>Conclusions</h4>DCP values in HCC patients undergoing hepatic arterial chemotherapy seem to be associated with OS and PFS. Thus, monitoring DCP values and observing the DCP response should be part of the management of patients undergoing transarterial chemotherapy.https://doi.org/10.1371/journal.pone.0225170
collection DOAJ
language English
format Article
sources DOAJ
author Ming Yang
Xuejun Zhang
Jinlong Liu
spellingShingle Ming Yang
Xuejun Zhang
Jinlong Liu
Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
PLoS ONE
author_facet Ming Yang
Xuejun Zhang
Jinlong Liu
author_sort Ming Yang
title Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
title_short Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
title_full Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
title_fullStr Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
title_full_unstemmed Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
title_sort prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: a systematic review and meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Background</h4>Serum des-γ-carboxy prothrombin (DCP) is a hepatocellular carcinoma (HCC) tumor marker that can be used to assess patient prognosis. Since the value of DCP in predicting the prognosis of hepatocellular carcinoma patients treated with transarterial chemotherapy remains controversial, we performed a meta-analysis of previous clinical studies.<h4>Methods</h4>A systematic literature search was performed using PubMed, the MEDLINE database, EMBASE, and the Cochrane Library in accordance with the PRISMA guidelines. The hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the effect size.<h4>Results</h4>Six respective cohort studies including a total of 943 cases were identified. The pooled results showed that low DCP was associated with a favorable overall survival (OS)(HR 0.653, 95% CI 0.444-0.960), and DCP response was associated with increased OS (HR 0.387,95% CI 0.215-0.697) and progression-free survival (PFS) (HR 0.42,95% CI 0.23-0.74) in HCC patients treated with transarterial chemotherapy.<h4>Conclusions</h4>DCP values in HCC patients undergoing hepatic arterial chemotherapy seem to be associated with OS and PFS. Thus, monitoring DCP values and observing the DCP response should be part of the management of patients undergoing transarterial chemotherapy.
url https://doi.org/10.1371/journal.pone.0225170
work_keys_str_mv AT mingyang prognosticvalueofdesgcarboxyprothrombininpatientswithhepatocellularcarcinomatreatedwithtransarterialchemotherapyasystematicreviewandmetaanalysis
AT xuejunzhang prognosticvalueofdesgcarboxyprothrombininpatientswithhepatocellularcarcinomatreatedwithtransarterialchemotherapyasystematicreviewandmetaanalysis
AT jinlongliu prognosticvalueofdesgcarboxyprothrombininpatientswithhepatocellularcarcinomatreatedwithtransarterialchemotherapyasystematicreviewandmetaanalysis
_version_ 1714806332739026944